FDA Center for Drug Evaluation and Research - What's New This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Compounding Quality Center of Excellence | Self-Guided Online Trainings
FDA Compounding Quality Center of Excellence ’s is providing anytime, anywhere training resources to support outsourcing facilities and other stakeholders in their efforts to enhance the quality of compounded drugs. FDA offers self-guided online courses offering continuing education, webinar recordin (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 26, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Compounding Quality Center of Excellence | Instructor-Led Trainings
The Compounding Quality Center of Excellence ’s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 26, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Roundup: January 26, 2024
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 26, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

10 Facts about What FDA Does and Does Not Approve
Is It Really"FDA Approved"? Maybe you ’ve seen these words on a company’s website or in a commercial promoting a product or treatment. Here are some facts about products that are, and aren’t, FDA approved. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 26, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi ® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing
Woburn, Massachusetts, Azurity Pharmaceuticals, Inc. is voluntarily recalling one (1) lot (F230169A) of Zenzedi ® CII (dextroamphetamine sulfate tablets, USP) 30 mg to the consumer level. The product is being recalled due to a report from a pharmacist in Nebraska who opened a bottle of Zenzedi® 30 m (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 25, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news